Taxotere (generic name: docetaxel) – new drug, which is described as being a chemotherapy drug, will be used to treat sufferers of head, neck, breast and lung cancers, was approved for use by the NHS in England and Wales last year.
Two years ago on the basis that it did not demonstrate value for money Taxotere was not approved.
Patients taking Taxotere had a 30% lower mortality rate than those receiving the standard treatment alone.
Taxotere, which was originally developed to treat breast cancer, has been shown to extend the survival time for men with prostate cancer by 25% over the standard treatment.
It is used when prostate cancer patients are no longer responding to hormone treatment, and reduces pain and weight loss.